A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Acebilustat (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMPIRE CF
- Sponsors Celtaxsys
- 17 May 2017 Status changed from recruiting to active, no longer recruiting, according to Celtaxsys media release.
- 17 May 2017 According to Celtaxsys media release, topline results from this study are expected in mid 2018.
- 05 May 2017 Planned End Date changed from 1 May 2018 to 1 Jun 2018.